R&D channel feed – Endpoints News

R&D channel feed

Updated: Merck, without sharing details, says RSV antibody successfully protected infants

9 months ago

Cellectar to seek approval for radioactive iodine-based therapy in rare blood cancer

9 months ago

Flagship launches AI-powered biologics biotech with $50M backing

9 months ago

GSK says Dovato was as effective as Biktarvy in head-to-head HIV trial — but patients gained less weight

9 months ago

Chinese biotech boasts competitive Phase 2b weight loss data for GLP-1 drug

9 months ago

Ionis flashes new Angelman syndrome data, will pursue Phase 3 trial next year

9 months ago

Roivant recently sold one spinout for billions. Is Priovant next?

9 months ago

George Church spinout raises $60M for protein therapies from genomically recoded organisms

9 months ago

Q&A: How argenx’s CEO plans to create a sequel to Vyvgart (and beat the IRA)

10 months ago

Aveo Oncology’s Fotivda combo fails in Phase 3 kidney cancer test

10 months ago

Novartis CEO: Trying to crack obesity market with another first-gen agent is 'not a prudent approach'

10 months ago

Parker Institute for Cancer Immunotherapy invests another $125M into research

10 months ago

J&J ditches epilepsy development with Addex, blindsiding 20-year partner

10 months ago

Roche touts Phase 3 Susvimo data in diabetes-related ophthalmic diseases

10 months ago

KRAS cancer drug eased symptoms of rare and serious blood vessel condition in two patients, new study shows

10 months ago

FDA thwarts Agenus' accelerated approval plans for CTLA-4/PD-1 combo in 'disappointing' move

10 months ago

Gilead chief medical officer Merdad Parsey to leave company early next year

10 months ago

Roche declares early win for oral GLP-1 drug it bought from Carmot

10 months ago

4DMT builds out case for wet AMD gene therapy with new Phase 2 data

10 months ago

Genentech parts ways with Relay Therapeutics on SHP2 after other pharma exits

10 months ago

Adverum prepares pivotal study for wet AMD gene therapy, touts Phase 2 data

10 months ago

Caribou to slash preclinical allogeneic CAR-NK work, lay off 12% of staff

10 months ago

Renalys raises $37.8M to take Travere's kidney disease drug into Phase 3 trial in Japan

10 months ago

After a handful of stumbles, argenx doubles down on pipeline-in-a-product strategy as it pitches investors

10 months ago

First page Previous page 33 34 353637 38 39 Next page Last page